Fibrinogen concentrate

ApprovedBiologic

GGold Coast Hospital and Health Service

Fibrinogen concentrate is one of 82 biologic programs targeting Liver Transplant. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Liver TransplantActive, not recruiting

HemorrhageActive, not recruiting

Postpartum HemorrhageActive, not recruiting

Liver TransplantApproved

Active, not recruiting

HemorrhagePhase 1/Phase 2

Active, not recruiting

Postpartum HemorrhagePhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

353 competitors in Liver Transplant

#DrugCompanyPhaseTrials

Fibrinogen concentrate

GGold Coast Hospital and Health Service

Approved

1 2

Lenvima

Eisai

Preclinical

2 3

Beyfortus

BeiGene

Preclinical

1 4

Prostigmin

Merck & Co.

Preclinical

1 5

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

4 6

Cyklokapron

AAmring

Preclinical

2 7

Valcyte

EEngelhard Arzneimittel GmbH & Co.KG

Preclinical

1 8

Tyvyt

Innovent Biologics (Suzhou) Co. Ltd.

Preclinical

1 9

Neo-Synephrine

EExela Pharma Sciences, LLC.

Preclinical

1 10

Levophed

GGeneral Hospital of Ningxia Medical University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Recruiting

Trauma

NCT05449834

Clinical

Trials by Indication[1]

Trauma4 trials

Fibrinogen in the Initial Resuscitation of Severe Trauma (FiiRST)

Completed·SSunnybrook Health Sciences Centre·Phase 1/2·NCT02203968·50 enrolled

Fibrinogen Early In Severe Trauma studY

Completed·GGold Coast Hospital and Health Service·Phase 2·NCT02745041·100 enrolled

Fibrinogen Early In Severe Trauma studY Junior

Unknown status·GGold Coast Hospital and Health Service·Phase 2·NCT03508141·44 enrolled

Show 1 more trial

Fibrinogen Early In Severe Trauma StudY II

Recruiting·—·Phase 3·NCT05449834·900 enrolled

Surgery1 trial

Fibrinogen as an Alternative to FFP in Aortic Surgery.

Completed·UUniversity of Edinburgh·Phase 4·NCT00994045·20 enrolled

Anticoagulation1 trial

Changes in Haemostasis After Therapeutic Plasmapheresis With Citrate Anticoagulation

Unknown status·UUniversity Medical Centre Ljubljana·N/A·NCT03801135·20 enrolled

Polytrauma1 trial

Early Administration of Fibrinogen in Polytraumatized Patients With Hypofibrinogenemia: a Randomized Feasibility Trial

Completed·UUniversity of Sao Paulo General Hospital·Phase 4·NCT02864875·32 enrolled

Safety and Efficacy1 trial

Safety and Efficacy of Fibrinogen Concentrate in Aortic Arch Surgery Involving Moderate Hypothermic Circulatory Arrest

Unknown status·HHongjia Zhang·Phase 2·NCT02542306·150 enrolled

10 more indications

Coagulopathy1 trial

Pre-hospital Administration of Fibrinogen in Trauma-Induced Coagulopathy

Not yet recruiting·UUnidade Local de Saude do Arco Ribeirinho·N/A·NCT06582420·52 enrolled

Cardiac Surgery1 trial

Fibrinogen Concentrate In Children Cardiac Surgery 2

Unknown status·FFilomena R B G Galas·Phase 4·NCT03884725·42 enrolled

Postpartum Hemorrhage1 trial

A Program to Evaluate Riastap® and FIBTEM® for the Early Control and Treatment of Postpartum Hemorrhage (PERFECT PPH)

Withdrawn·YYale University·Phase 1/2·NCT02528708

After Cardiac Surgery1 trial

Fibrinogen Concentrate In Children After Cardiac Surgery

Completed·UUniversity of Sao Paulo·Phase 2·NCT01187225·63 enrolled

Treatment1 trial

Fibrinogen Concentrate as Initial Treatment for Postpartum Haemorrhage: A Randomised Clinically Controlled Trial

Completed·—·Phase 2/3·NCT01359878·249 enrolled

First-line Treatment1 trial

Platelets or Fibrinogen as First-line Treatment for Bleeding During Pedatric Heart Surgery

Unknown status·SSahlgrenska University Hospital·Phase 2·NCT04807621·40 enrolled

Liver Transplant1 trial

Impact of Two Guided Transfusion Strategies on Blood Product Requirements in Liver Transplantation.

Unknown status·AAntoni Sabaté Pes·Phase 4·NCT04405518·188 enrolled

Cardiopulmonary Bypass1 trial

In Vivo Effects of Fibrinogen Concentrate (FC) Versus Cryoprecipitate on the Neonatal Fibrin Network Structure After Cardiopulmonary Bypass (CPB)

Completed·EEmory University·Phase 3·NCT03932240·36 enrolled

Hemorrhage1 trial

Transfusion of Red Blood Cells, Tranexamic Acid and Fibrinogen Concentrate for Severe Trauma Hemorrhage at Pre-hospital Phase of Care.

Completed·BBanc de Sang i Teixits·Phase 1/2·NCT03780894·79 enrolled

Unspecified1 trial

Fibrinogen Concentrate vs Cryoprecipitate

Completed·SStanford University·Phase 4·NCT03014700·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 18 trial records for Fibrinogen concentrate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Fibrinogen concentrate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Fibrinogen concentrate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Gold Coast Hospital and Health Service company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Approved[1]
Company: GGold Coast Hospital and Health Service

Fibrinogen concentrate

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Trauma4 trials

Surgery1 trial

Anticoagulation1 trial

Polytrauma1 trial

Safety and Efficacy1 trial

Coagulopathy1 trial

Cardiac Surgery1 trial

Postpartum Hemorrhage1 trial

After Cardiac Surgery1 trial

Treatment1 trial

First-line Treatment1 trial

Liver Transplant1 trial

Cardiopulmonary Bypass1 trial

Hemorrhage1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News